Go to the list of all blogs
Sergey Savastiouk's Avatar
published in Blogs
Jul 26, 2026
Rocket Lab (RKLB) Needs a +56% Rally to Reach $100 – What Stands in the Way

Rocket Lab (RKLB) Needs a +56% Rally to Reach $100 – What Stands in the Way

Key Takeaways

  • Rocket Lab shares closed at $63.91 on July 24, 2026, meaning the stock would need to climb approximately 56% to reclaim the psychologically significant $100 level.
  • The strongest bullish catalyst is Neutron, the company's medium-lift reusable rocket targeting a debut launch in the fourth quarter of 2026, which could unlock a $5.6 billion national security launch program and dramatically expand the revenue base.
  • Rocket Lab's record $2.2 billion backlog and 63.5% year-over-year revenue growth in Q1 2026 demonstrate strong operational momentum, while the pending $8 billion Iridium acquisition could transform the company into a vertically integrated space platform with recurring services revenue.
  • Valuation and dilution risks remain significant obstacles. The stock trades at roughly 66 times trailing sales, insider selling has weighed on sentiment, and a $3 billion at-the-market equity offering has raised concerns about shareholder dilution.
  • Wall Street consensus suggests $100 is achievable. The average analyst price target stands near $110, with most targets clustering between $96 and $135, though the Street-low target of $60 underscores the wide range of possible outcomes.

Why Investors Are Watching the $100 Level

After peaking near $151 in May 2026, Rocket Lab Corporation (NASDAQ: RKLB) has endured a punishing drawdown of more than 55%, wiping out the year's gains and sending shares tumbling into the mid-$60s. The speed and severity of the sell-off — driven by a broader post-SpaceX IPO rotation out of space stocks, a dilutive equity offering, and a securities class action — has left investors asking whether the stock can mount a meaningful recovery. The $100 round-number level has emerged as the most visible near-term milestone: it sits just below the analyst consensus, represents the threshold that separated the stock's rally phase from its correction, and carries the psychological weight that round numbers command in technical analysis.

Company Overview

Rocket Lab is an end-to-end space company headquartered in Long Beach, California, founded in 2006 by CEO Sir Peter Beck. Unlike pure-play launch providers, Rocket Lab operates across two segments: Launch Services, anchored by the frequently flown Electron small orbital rocket, and Space Systems, which designs and manufactures satellites, spacecraft components, and on-orbit infrastructure. The company has delivered more than 1,700 satellites to orbit, operates three launch pads across New Zealand and Virginia, and is developing Neutron, a medium-lift reusable rocket designed to compete directly with SpaceX's Falcon 9 in the constellation-deployment and national security markets. I also checked this using Tickeron’s AI Screener to see how the stock compares to others in the industry.

What Could Drive the Stock Back to $100

The single most important variable for the Rocket Lab thesis is Neutron's debut flight, now targeted for the fourth quarter of 2026. A successful first launch would make Rocket Lab eligible to compete for individual task orders under the Space Force's National Security Space Launch (NSSL) Phase 3 Lane 1 program, a contract vehicle carrying a $5.6 billion ceiling through 2029. The Archimedes engine that powers Neutron recently completed a full-duration qualification burn at NASA's Stennis Space Center — a milestone that keeps the timeline credible despite an earlier tank-test failure that pushed the schedule from mid-2026 into the fourth quarter.

Beyond Neutron, the fundamental momentum is difficult to dismiss. First-quarter fiscal 2026 revenue reached $200.35 million, up 63.5% year over year, while the contracted backlog swelled to a record $2.2 billion. Rocket Lab also secured an $816 million Space Development Agency contract for 18 tracking-layer satellites and was selected alongside Raytheon for the Golden Dome Space-Based Interceptor program — placing the company at the center of the highest-priority U.S. defense space budgets.

The pending $8 billion acquisition of Iridium Communications, announced in late June 2026, represents a transformative bet. If the deal closes as expected in mid-2027, Rocket Lab would add a global satellite communications network, L-band spectrum, and more than 2.5 million recurring subscribers — evolving from a launch provider into a vertically integrated space platform that more closely resembles the SpaceX model Morgan Stanley has cited in its analysis.

Analyst Consensus: Cautious Optimism

The broader analyst community remains constructive despite the sell-off. Across 22 analysts, the consensus rating is Moderate Buy, with an average price target of approximately $110, implying roughly 72% upside from the most recent close. High-profile targets include Needham at $120, Keybanc at $135, and Bank of America at $115. Morgan Stanley maintains an Overweight rating with a $105 base case while simultaneously raising its bull-case scenario to $293, reflecting the optionality tied to Neutron, Iridium, and Golden Dome contract conversions. On the more cautious side, Piper Sandler initiated coverage in mid-July with a Neutral rating and an $83 target, arguing the stock remains expensive even after falling more than 50% from its peak. The range of opinion — from $60 at Wells Fargo to $150 at the high end — underscores how much depends on execution over the next two quarters.

Risks That Could Prevent the Move

Rocket Lab remains an unprofitable company. Fiscal 2025 revenue of $601.8 million was accompanied by a net loss of $198 million, and the company trades at roughly 66 times trailing sales — a multiple that prices in years of flawless execution. Any Neutron delay beyond late 2026, whether from technical setbacks or certification hurdles, would delay the medium-lift revenue stream that the valuation thesis depends on and could trigger further equity dilution.

Additional headwinds include a $3 billion at-the-market equity offering announced in June, which raised dilution concerns, and insider selling from CEO Peter Beck, who disclosed the sale of nearly 3 million shares in early July. A securities class action filed over Neutron timeline disclosures has added legal uncertainty to the mix. Meanwhile, the post-SpaceX IPO rotation has not yet run its course, and with a beta of approximately 2.55, RKLB amplifies every shift in market sentiment — in both directions.

Technical Levels That Matter

From a technical perspective, $100 also aligns as the approximate midpoint between the 52-week high of $151 and key support near $60 — the Street-low analyst target and a level the stock tested during the recent sell-off. The 200-day simple moving average, sitting around $76, represents a nearer-term hurdle; the stock would need to reclaim that level before any sustained move toward triple digits gains credibility. The $80 to $85 zone, where the stock consolidated during portions of June and early July, may also act as an intermediate resistance area. I reviewed the recent patterns using Tickeron’s AI Pattern Search Engine to confirm the key levels.

Using AI Tools to Navigate Volatile Names

One tool I’ve found helpful for navigating stocks like this is Tickeron’s AI Daily Buy/Sell Signals. It uses artificial intelligence to continuously monitor thousands of stocks and ETFs, generating Buy, Sell, or Hold signals based on evolving market conditions, technical patterns, and AI-driven analysis. Rather than manually scanning charts and news feeds, I can use these signals to identify emerging opportunities, monitor existing positions, and spot shifts in market trends more efficiently. For investors tracking whether RKLB can sustain a recovery toward $100, automated signal monitoring can help filter the noise from the signal.

Final Assessment

Can Rocket Lab reach $100? The arithmetic says yes — a 56% rally from $63.91 is well within this stock's normal range of motion, and it has already traded well above $100 earlier in 2026. The question is less about capability and more about timing and conditions. A clean Neutron debut in the fourth quarter, continued backlog conversion at or above current growth rates, and tangible progress on the Iridium integration would likely provide the fundamental fuel to drive shares back through $100. Conversely, a Neutron delay into 2027, further dilution, or deteriorating sentiment across the space sector would make that target considerably more difficult. For now, $100 remains a reachable but non-trivial milestone — one that demands execution, not merely ambition. The upcoming Q2 earnings report on August 6 may offer the next meaningful signal about which direction the stock is poised to take.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Related Ticker: RKLB

Contributor

<p>Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years&nbsp;developing&nbsp;his proprietary trading and quantitative algorithms (now Tickeron&rsquo;s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional,&nbsp;sophisticated stock market analysis capabilities to retail investors via&nbsp;an easy-to-use interface.</p>


RKLB's RSI Indicator recovers from oversold territory

The RSI Oscillator for RKLB moved out of oversold territory on July 30, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 29 similar instances when the indicator left oversold territory. In of the 29 cases the stock moved higher. This puts the odds of a move higher at .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on August 03, 2026. You may want to consider a long position or call options on RKLB as a result. In of 90 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for RKLB just turned positive on July 31, 2026. Looking at past instances where RKLB's MACD turned positive, the stock continued to rise in of 44 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where RKLB advanced for three days, in of 299 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where RKLB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

RKLB broke above its upper Bollinger Band on August 04, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for RKLB entered a downward trend on August 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating fairly steady price growth. RKLB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 72, placing this stock slightly better than average.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.877) is normal, around the industry mean (10.193). P/E Ratio (0.000) is within average values for comparable stocks, (64.003). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (8.261). Dividend Yield (0.000) settles around the average of (0.016) among similar stocks. P/S Ratio (61.728) is also within normal values, averaging (35.983).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

Notable companies

The most notable companies in this group are GE Aerospace (NYSE:GE), Boeing Company (NYSE:BA), Lockheed Martin Corp (NYSE:LMT), Northrop Grumman Corp (NYSE:NOC), Virgin Galactic Holdings (NYSE:SPCE).

Industry description

Aerospace & Defense is one of largest industries in the U.S., mainly comprising the following areas: commercial airliners, military aircraft, missiles, space, and general aviation. Focused heavily on research & development, it is also one of the fastest growing industries. Military aircraft has the largest market share in the industry’s sales, followed by space systems, civil aircraft, and missiles. Aerospace exports, directly and indirectly, support more jobs than the export of any other commodity, according to a study by the U.S. Department of Commerce. Boeing Company, Lockheed Martin Corporation and General Electric Company are some of the most prominent players in this space.

Market Cap

The average market capitalization across the Aerospace & Defense Industry is 38.24B. The market cap for tickers in the group ranges from 4.49 to 1.43T. SPCX holds the highest valuation in this group at 1.43T. The lowest valued company is BDRPF at 4.49.

High and low price notable news

The average weekly price growth across all stocks in the Aerospace & Defense Industry was 9%. For the same Industry, the average monthly price growth was 0%, and the average quarterly price growth was 3%. VOYG experienced the highest price growth at 60%, while DFNS experienced the biggest fall at -46%.

Volume

The average weekly volume growth across all stocks in the Aerospace & Defense Industry was 51%. For the same stocks of the Industry, the average monthly volume growth was 42% and the average quarterly volume growth was 26%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 47
P/E Growth Rating: 66
Price Growth Rating: 57
SMR Rating: 79
Profit Risk Rating: 72
Seasonality Score: -21 (-100 ... +100)
View a ticker or compare two or three
RKLB
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
A.I.Advisor
published price charts
Last 5 trading days
A.I. Advisor
published General Information

General Information

Industry AerospaceDefense

Profile
Details
Industry
N/A
Address
3881 McGowen Street
Phone
+1 714 465-5737
Employees
2600
Web
https://www.rocketlabusa.com
Interact to see
Advertisement
Novartis (NVS) reports Q4/FY 2025 earnings on February 4, 2026, with consensus calling for ~$1.99 EPS on ~$13.7 billion in revenue. Sanofi (SNY) delivered strong FY 2025 results on January 29, reporting €43.6 billion in sales (+9.9% CER) and 15% business EPS growth.
Novo Nordisk (NVO) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $11.96 billion in revenue and $0.89 EPS, reflecting a moderation in GLP-1 growth. Eli Lilly (LLY) is expected to report around the same time, with projections of $17.87 billion in revenue and $6.99 EPS, driven by continued volume gains from Mounjaro and Zepbound.
MUFG is expected to report Q3 FY2026 EPS of about $0.30, broadly in line with its recent pattern of earnings beats.
Banco Santander (SAN) reports Q4 2025 earnings on February 4, 2026, following record nine-month attributable profit of €10.3 billion, up 11% year over year.
Uber (UBER) reports Q4 2025 earnings on February 4, 2026, with consensus estimates of $0.78 EPS and $14.32 billion in revenue, up about 20% year over year.
Qualcomm’s Q1 FY2026 report, covering the period ended December 28, 2025, arrives amid a pivotal shift in the semiconductor landscape. While handset growth moderates, the company is expanding in automotive, IoT, and AI-enabled devices.
UBS Group AG reports Q4 2025 earnings on February 4, 2026, with consensus EPS ranging $0.25–$0.67 and revenue around $11.62 billion, down YoY. HSBC Holdings plc reports Q4 earnings on February 25, 2026, with consensus EPS ~$1.57; Q3 showed resilient net interest income despite $1.4B in legal provisions.
Boston Scientific’s Q4 caps a transformative year, driven by ~15.5% organic growth from WATCHMAN, FARAPULSE electrophysiology, and MedSurg expansions. As a leader in minimally invasive devices, BSX’s results set the benchmark against Medtronic and Stryker—diversified medtech giants navigating tariffs, procedural rebounds, and innovation.
Arm, the leading provider of energy-efficient processor designs powering over 99% of smartphones and expanding into AI data centers, faces high scrutiny in Q3 FY2026 (ending Dec 31, 2025). After a strong Q2 with record royalty and licensing revenue, investors are focused on whether AI demand will continue to drive robust growth.
CME Group (CME): Q4 2025 earnings due February 4, 2026; consensus expects adjusted EPS $2.75 and revenue ~$1.6B. S&P Global (SPGI): Q4 2025 earnings due February 10, 2026; Q3 posted EPS $4.73 and 9% revenue growth, driven by Ratings, Indices, and Market Intelligence.
Datadog (DDOG) has come under pressure in recent sessions as volatility across the software sector weighs on sentiment ahead of earnings. Trading in the $108–120 range following a pullback from highs near $200, the stock reflects a disconnect between near-term market caution and resilient underlying fundamentals.
Starbucks shares have shown renewed strength in recent trading, rebounding from earlier lows within a 52-week range of $75.50 to $117.46. The recovery reflects improving comparable sales trends and a return to transaction growth, suggesting early progress from operational initiatives aimed at reconnecting with customers.
DoorDash holds a Strong Buy consensus from 33 analysts, with an average 12-month price target of $280.82, implying more than 40% upside from recent trading levels.
Amazon’s Q4 report capped a strong year marked by accelerating cloud growth, steady retail execution, and expanding advertising profitability. The results reinforced Amazon’s positioning as a core beneficiary of enterprise AI demand, particularly through AWS, while highlighting improving operating leverage across the broader business.
ConocoPhillips reported Q4 2025 adjusted EPS of $1.02, below consensus of $1.08, driven by weaker realized commodity prices.
ICE reported Q4 2025 net revenues of $2.5 billion, up 8% year-over-year, capping 20 consecutive years of record annual revenues at $9.9 billion.
Eli Lilly’s Q4 results highlight explosive growth from GLP-1 therapies, cementing leadership in obesity and diabetes. The company’s strong revenue beat and robust 2026 guidance illustrate high-growth pharma dynamics. Johnson & Johnson, in contrast, exemplifies a diversified healthcare strategy, combining pharmaceuticals, MedTech, and consumer health for steady expansion.
Eli Lilly (LLY), AbbVie (ABBV), and Merck (MRK) all reported strong Q4 2025 earnings, but the market reacted differently to each, reflecting variations in growth profiles, product concentration, and sector dynamics. AbbVie delivered Q4 revenue of $16.62 billion, up 10% year-over-year, with full-year revenue reaching $61.2 billion, an 8.6% increase. Adjusted EPS came in at $2.71, surpassing consensus, though shares dipped following the report amid ongoing Humira concerns
Novo Nordisk (NVO) reported Q4 2025 EPS of $1.02, surpassing estimates of $0.92, with revenue of $12.53B vs $11.99B expected. Full-year 2025 sales rose 10% at constant exchange rates (CER) to DKK 309B, but 2026 guidance anticipates a 5–13% decline at CER due to pricing pressures. Novartis (NVS) posted Q4 core EPS of $2.03, beating $1.99 estimates; net sales of $13.34B slightly missed consensus. FY sales grew 8%, with core EPS up 17% to $8.98.
MUFG (Mitsubishi UFJ Financial Group) posted Q3 FY2026 profits of ¥1.81 trillion, up 3.7% YoY, on track for its full-year target of ¥2.1 trillion. HSBC is set to report Q4 FY2025 earnings on Feb 25, 2026, with consensus EPS around $1.60; recent quarters showed resilient net interest income (NII) supported by Asia wealth growth.